Expert Interviews
Advertisement
Dr. Spratt ponders the evolving integration of RT with systemic treatments, challenges in counseling patients, and more.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Dr. Gomella tells his journey to becoming a urologist, the importance of multidisciplinary care, and challenges in the field.
Dr. Gupta traces the trajectory of her career and describes her commitment to advancing the field through innovative trials.
Dr. James Sylora shares his career, patient care, and vision for surgical and therapy advancements in community urology.
Drs. Ambinder and Elsamra explore robotic surgery, including its applicability, patient benefits, and evolving role.
Dr. Kirsh discusses his distinguished career and the evolution of urology practice in the United States.
Dr. Wei helped uncover genetic, transcriptional, and immune differences in TFE3-rearranged RCC versus papillary, ccRCC.
Dr. Grivas shares insights into his career trajectory, driven by a passion to revolutionize the care of patients with UC.
Drs. Smith and Wallis shed light on how urologists can reduce risks and improve the well-being of their female patients.
Dr. Fleming details his early-phase clinical trial work that has had the largest impact on patients with GU malignancies.
Dr. Black shares the basis for testing atezolizumab in BCG-unresponsive NMIBC as well as the implications of SWOG S1605.
Hans Hammers, MD, PhD – Driving Immunotherapy Combinations Into the Modern Age of Kidney Cancer Care
Dr. Hammers discusses the kidney clinical trials he has led and shares his perspectives on novel IO and targeted therapies.
Dr. Sonpavde expounds on the current state and momentum of research efforts to advance treatment strategies in MIBC.
Dr. Siefker-Radtke shares the novel targeted therapies for bladder cancer and how they are assessed in combinations.
Dr. Msaouel shares his journey to becoming a world expert in RMC and the clinical trial work he led to improve outcomes.
Katherine Virgo, PhD, MBA, provided insight into ASCO's updated guideline for the management of metastatic prostate cancer.
Michigan Urological Surgery and Improvement Collaborative is an effort to improve patient lives through high-quality care.
A recent study examined safety and efficacy from the ARASENS trial for certain subgroups by disease volume and risk.
Dr. A. Ari Hakimi discusses how cytoreductive nephrectomy has evolved and is being used in today’s mRCC treatment paradigm.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.